

**THE JORDANIAN PHARMACEUTICAL MANUFACTURING CO.**

**PUBLIC SHAREHOLDING COMPANY**

**INTERIM CONDENSED CONSOLIDATED**  
**FINANCIAL STATEMENTS (UNAUDITED)**

**31 MARCH 2024**

## **Report on Review of Interim Condensed Consolidated Financial Statements**

**To the Chairman and Board of Directors Members**

**The Jordanian Pharmaceutical Manufacturing Company - Public Shareholding Company**

Amman - Jordan

### **Introduction**

We have reviewed the accompanying interim condensed consolidated financial statements of The Jordanian Pharmaceutical Manufacturing Company – Public Shareholding Company (the "Company") and its subsidiaries (the "Group") as at 31 March 2024, comprising of the interim consolidated statement of financial position as at 31 March 2024 and the related interim consolidated statements of profit or loss, comprehensive income, changes in equity and cash flows for the three months period then ended and explanatory information. The management is responsible for the preparation and presentation of these interim condensed consolidated financial statements in accordance with International Accounting Standard IAS 34 (Interim Financial Reporting). Our responsibility is to express a conclusion on these interim condensed consolidated financial statements based on our review.

### **Scope of Review**

We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### **Conclusion**

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim condensed financial statements are not prepared, in all material respects, in accordance with IAS 34.



### **Emphasis of Matter**

Without qualifying our conclusion,

As described in Note (1) to Consolidated financial statements, The Company has announced, In its general assembly meeting held on 21 April 2024, Jordan Islamic Bank intentions to transfer its shares in the Company to new investor, in return to transferring Jordan Islamic Bank net direct debt due from The Jordanian Pharmaceutical Manufacturing Company to the new investors, currently work is carried on the legal formalities in regard to this matter.

the Group incurred losses by the amount of JD 542,340 during the three months ended 31 March 2024 and the accumulated losses reached to JD 36,600,691 as of 31 March 2024. The Groups' ability to realize its assets and continue its operations is subject to its ability to achieve revenues from operations and obtain required financing, if needed, to settle its commitments when they come due, the accompanying consolidated financial statements are prepared on going concern basis.

### **Business Solutions for Auditing**

Amman - Jordan  
29 April 2024



**THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY**  
**INTERIM CONSOLIDATED STATEMENT OF FINANCIAL POSITION**  
**AS AT 31 MARCH 2024**

	Note	31 March 2024 JD (Unaudited)	31 December 2023 JD (Audited)
<b><u>ASSETS</u></b>			
<b>Non-current assets -</b>			
Right-of-use assets		7,190,554	7,228,880
Property, plant and equipment	3	4,276,928	4,312,811
Intangible assets		2,083,700	2,112,053
Investment in associates		4,377,124	3,640,067
Deferred tax assets		1,231,515	1,231,515
Financial assets at fair value through other comprehensive income		319,419	319,419
		<u>19,479,240</u>	<u>18,844,745</u>
<b>Current assets -</b>			
Inventory		7,881,032	6,621,673
Other receivables		810,092	941,320
Due from related parties	4	1,182,968	1,182,968
Accounts receivable		11,468,515	13,616,143
Checks under collection		647,314	664,855
Cash and bank balances	5	180,332	615,769
		<u>22,170,253</u>	<u>23,642,728</u>
<b>Total Assets</b>		<u>41,649,493</u>	<u>42,487,473</u>
<b><u>EQUITY AND LIABILITIES</u></b>			
<b>Attributable to equity holders of the Parent Company -</b>			
Paid in capital	1	69,756,944	69,756,944
Share discount	1	(32,444,444)	(32,444,444)
Statutory reserve		216,424	216,424
Cumulative change in fair value through other comprehensive income		(2,197,632)	(2,197,632)
Accumulated losses		(36,600,691)	(36,058,854)
		<u>(1,269,399)</u>	<u>(727,562)</u>
Non-controlling interests		157,565	158,068
<b>Net Equity</b>		<u>(1,111,834)</u>	<u>(569,494)</u>
<b><u>Liabilities</u></b>			
<b>Non-current liabilities -</b>			
Deferred gain from sale and lease back		947,575	976,289
Lease liabilities		5,851,529	5,986,774
Murabaha financing		19,802,551	20,357,971
Notes payables		3,877,831	4,117,851
		<u>30,479,486</u>	<u>31,438,885</u>
<b>Current liabilities -</b>			
Deferred gain on sale and lease back due within a year		114,858	114,858
Lease liabilities due within a year	6	654,055	638,133
Murabaha financing due within a year		2,301,733	1,594,565
Notes payables due within a year		969,358	971,417
Due to related parties	4	986,190	986,190
Accounts payable		2,418,164	2,446,877
Other payables		4,837,483	4,866,042
		<u>12,281,841</u>	<u>11,618,082</u>
<b>Total Liabilities</b>		<u>42,761,327</u>	<u>43,056,967</u>
<b>Total Equity and Liabilities</b>		<u>41,649,493</u>	<u>42,487,473</u>

The accompanying notes from 1 to 12 form integral part of these consolidated financial statements

**THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY**  
**INTERIM CONSOLIDATED STATEMENT OF PROFIT OR LOSS**  
**FOR THE THREE MONTHS ENDED 31 MARCH 2024 (UNAUDITED)**

	Note	For the three months ended 31 March	
		2024	2023
		JD	JD
Net sales		2,247,820	2,044,664
Cost of sales		(1,518,707)	(2,251,437)
<b>Gross profit (loss)</b>		<b>729,113</b>	<b>(206,773)</b>
Selling and distribution expenses		(677,256)	(493,982)
Administrative expenses		(634,650)	(553,558)
Donations		-	(290,570)
Finance costs		(176,819)	(310,786)
Research and study expenses		(102,704)	(98,798)
Impairment and amortization of Intangible assets		(31,577)	(28,644)
Expired goods		(27,516)	(162,114)
Impairment Inventory		(100,000)	-
Groups' share of associates net profits		737,057	-
Other income and expenses, net		(257,988)	(27,138)
<b>loss for the period before income tax</b>		<b>(542,340)</b>	<b>(2,172,363)</b>
Income tax expense for the period		-	-
<b>loss for the period</b>		<b>(542,340)</b>	<b>(2,172,363)</b>
<b>loss for the period attributable to:</b>			
Shareholders of the parent company		(541,837)	(2,166,470)
Non-controlling interests		(503)	(5,893)
		<b>(542,340)</b>	<b>(2,172,363)</b>
		JD/Fils	JD/Fils
<b>Basic and diluted Profit per share for the year attributable to shareholders of the parent company</b>	8	<b>(0/008)</b>	<b>(0/031)</b>

**THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY**  
**INTERIM CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME**  
**FOR THE THREE MONTHS ENDED 31 MARCH 2024 (UNAUDITED)**

	For the three months ended 31 March	
	2024	2023
	JD	JD
<b>loss for the year</b>	(542,340)	(2,172,363)
<b>Other comprehensive income items that may be reclassified to profit or loss in subsequent periods, net of tax</b>		
Changes in fair value of financial assets at fair value through other comprehensive income	-	-
<b>Total comprehensive income for the period</b>	<u>(542,340)</u>	<u>(2,172,363)</u>
<b>Total comprehensive income for the period attributable to:</b>		
Shareholders of the parent company	(541,837)	(2,166,470)
Non-controlling interests	<u>(503)</u>	<u>(5,893)</u>
	<u>(542,340)</u>	<u>(2,172,363)</u>

**THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY**  
**INTERIM CONSOLIDATED STATEMENT OF CHANGES IN EQUITY**  
**FOR THE THREE MONTHS ENDED 31 MARCH 2024 (UNAUDITED)**

	Attributable to equity holders of the parent company						
	Paid-in capital	Share discount	Statutory reserve	Cumulative change in fair value of financial assets at fair value through other comprehensive income		Accumulated losses	Total
				JD	JD		
<b>2024-</b>	JD	JD	JD	JD	JD	JD	JD
Balance as at 1 January 2024	69,756,944	(32,444,444)	216,424	(2,197,632)	(36,058,854)	158,068	(569,494)
Total comprehensive income for the period	-	-	-	-	(541,837)	(503)	(542,340)
Balance as at 31 March 2024	69,756,944	(32,444,444)	216,424	(2,197,632)	(36,600,691)	157,565	(1,111,834)
<b>2023-</b>							
Balance as at 1 January 2023	69,756,944	(32,444,444)	216,424	(2,197,632)	(32,202,985)	153,243	2,281,550
Total comprehensive income for the period	-	-	-	-	(2,166,470)	(5,893)	(2,172,363)
Balance as at 31 March 2023	69,756,944	(32,444,444)	216,424	(2,197,632)	(35,369,455)	147,350	109,187

The accompanying notes from 1 to 12 form integral part of these consolidated financial statements

**THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY**  
**INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS**  
**FOR THE THREE MONTHS ENDED 31 MARCH 2024 (UNAUDITED)**

		For the three months ended 31 March	
	Note	2024	2023
		JD	JD
<b><u>OPERATING ACTIVITIES</u></b>			
Loss for the period		(542,340)	(2,172,363)
<b>Adjustments for:</b>			
Depreciation and amortization		221,697	209,295
Group's share of associates net profits		(737,057)	-
Finance costs		176,819	310,786
		(880,881)	(1,652,282)
<b>Changes in working capital -</b>			
Inventories		(1,259,359)	199,998
Accounts receivable		2,147,628	4,391,586
Letters of credit under collection		-	150,447
Checks under collection		17,541	(453,967)
Other receivables		131,228	309,899
Accounts payable		(28,713)	(463,752)
Other payables		(28,559)	(509,789)
Due to related parties		-	(256,258)
<b>Net cash flows from operating activities</b>		<b>98,885</b>	<b>1,715,882</b>
<b><u>INVESTING ACTIVITIES</u></b>			
Purchase of property, plant and equipment	3	(119,135)	(683,423)
<b>Net cash flows used in investing activities</b>		<b>(119,135)</b>	<b>(683,423)</b>
<b><u>FINANCING ACTIVITIES</u></b>			
Lease liabilities paid		(148,037)	(143,781)
Notes payables		(242,079)	(241,664)
Murabaha financing received		151,748	(251,017)
Finance costs paid		(176,819)	(310,786)
<b>Net cash flows used in financing activities</b>		<b>(415,187)</b>	<b>(947,338)</b>
<b>Net (decrease) increase in cash and cash equivalents</b>		<b>(435,437)</b>	<b>85,121</b>
Cash and cash equivalents at the beginning of the year	5	615,769	2,608,016
<b>Cash and cash equivalents at the end of the year</b>	<b>5</b>	<b>180,332</b>	<b>2,693,137</b>

The accompanying notes from 1 to 12 form integral part of these consolidated financial statements

**THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY**  
**NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**31 MARCH 2024 (UNAUDITED)**

---

**(1) GENERAL**

The Jordanian Pharmaceutical Manufacturing Company (the "Company") was established on 27 January 2004 as a Public Shareholding Company, as a result of the merger between Al Razi for Pharmaceutical Manufacturing a public shareholding company and the Jordanian Company for the Production of Medicines and Medical Equipment a limited liability company, under registration number 347 with an authorized capital and paid in capital of JD 69,756,944 divided into 69,756,944 shares at par value of JD1 per share.

The head office of the Company is located in Amman - The Hashemite Kingdom of Jordan.

The Group's main objectives are the production of medical, chemical and pharmaceutical products.

The consolidated financial statements were approved by the Board of Directors on 29 April 2024.

**INVESTORS WITH SIGNIFICANT INFLUENCE ON THE GROUP:**

Jordan Islamic Bank and Rimco for Investment Company owns 88.8% and 4.6% of the Company's issued shares, respectively.

In its general assembly meeting held on 21 April 2024, The Company has announced Jordan Islamic Bank intentions to transfer its shares in the Company to new investor, in return to transferring Jordan Islamic Bank net direct debt due from The Jordanian Pharmaceutical Manufacturing Company to the new investors, currently work is carried on the legal formalities in regard to this matter.

**(2-1) BASIS OF PREPARATION**

The interim condensed consolidated financial statements for the period ended on 31 March 2024 are prepared in accordance with IAS 34 ("Interim Financial Information").

The interim condensed consolidated financial statements are presented in Jordanian Dinars ("JD") which is the functional currency of the Company.

The interim condensed consolidated financial statements have been prepared on a historical cost basis, except for financial assets at fair value through other comprehensive income that have been measured at fair value as at the date of the interim condensed consolidated financial statements.

The interim condensed consolidated financial statements do not contain all information and disclosures required for full financial statements prepared in accordance with International Financial Reporting Standards, and should be read in conjunction with the Company's annual financial statements as at 31 December 2023. In addition, the results for the three months ended 31 March 2024 are not necessarily indicative of the results that may be expected for the financial year ending on 31 December 2024.

**THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY**  
**NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**31 MARCH 2024 (UNAUDITED)**

---

**(2-2) CHANGES IN ACCOUNTING POLICES**

The accounting policies adopted in the preparation of the condensed consolidated financial statements are consistent with those followed in the preparation of the Company's annual consolidated financial statements for the year ended 31 December 2023, except for the adoption of new standards effective as of 1 January 2024:

**Supplier Finance Arrangements - Amendments to IAS 7 and IFRS 7**

In May 2023, the IASB issued amendments to IAS 7 Statement of Cash Flows and IFRS 7 Financial Instruments: Disclosures to clarify the characteristics of supplier finance arrangements and require additional disclosure of such arrangements. The disclosure requirements in the amendments are intended to assist users of financial statements in understanding the effects of supplier finance arrangements on an entity's liabilities, cash flows and exposure to liquidity risk.

The amendments had no impact on the group's consolidated financial statements.

**Amendments to IFRS 16: Lease Liability in a Sale and Leaseback**

In September 2022, the IASB issued amendments to IFRS 16 to specify the requirements that a seller-lessee uses in measuring the lease liability arising in a sale and leaseback transaction, to ensure the seller-lessee does not recognise any amount of the gain or loss that relates to the right of use it retains.

The amendments had no impact on the group's consolidated financial statements.

**Amendments to IAS 1: Classification of Liabilities as Current or Non-current**

In January 2021, the IASB issued amendments to paragraphs 69 to 76 of IAS 1 to specify the requirements for classifying liabilities as current or non-current. The amendments clarify: what is meant by a right to defer settlement, the right to defer must exist at the end of the reporting period, that classification is unaffected by the likelihood, that an entity will exercise its deferral right, and that only if an embedded derivative in a convertible liability is itself an equity instrument would the terms of a liability not impact its classification.

The amendments had no impact on the group's consolidated financial statements.

**THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY**  
**NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**31 MARCH 2024 (UNAUDITED)**

---

**(2-3) BASIS OF CONSOLIDATION**

The interim condensed consolidated financial statements comprise the financial statements of the Company and its subsidiaries (the "Group") as at 31 March 2024. The subsidiaries that are included in the consolidated financial statements are as follow:

Company Name	Capital (JD)	Main activities	Country of incorporation	Ownership percentage
Dellas for Natural Products Co.	150,000	Pharmaceutical industries	Jordan	93.33%
Swagh for Pharmaceutical Manufacturing Co.	150,000	Pharmaceutical industries	Jordan	93.33%
Aragen for Technical Organic Co. and its subsidiary: *	1,400,000	Reagent industries	Jordan	100%
- Aragen for Technical Organic Co. (Free-Zone)	30,000	Pharmaceutical industries	Jordan	100%
Mukalafa Import Export Company	10,000	Pharmaceutical marketing	Jordan	51%

The control exists when the Group controls the subsidiaries' significant and relevant activities, and is exposed, or has the rights, to variable returns from its involvement with the subsidiaries, and has the ability to affect those returns. Control over the subsidiaries is exercised when the following factors exist:

- Power over the investee (i.e., existing rights that give it the current ability to direct the relevant activities of the investee).
- Exposure, or rights, to variable returns from its involvement with the investee.
- The ability to use its power over the investee to affect its returns.

When the Group owns less than a majority of the voting rights in an investee, in this case, the Group considers all factors and circumstances to determine whether it has control over the investee, which include the following:

- Contractual agreements with shareholders that have voting rights in the investee.
- Rights resulting from other contractual arrangements.
- The Group's current and future voting rights in the investee.

The Group reassesses its control over the investee when circumstances and factors exist that lead to the change in one or more of the three factors listed above.

Subsidiaries are fully consolidated from the date of acquisition being the date on which the Group gains control, and continues to do so until the date when such control ceases. The subsidiaries revenues and expenses are consolidated in the consolidated statement of comprehensive income from the date the Group gains control over the subsidiaries until that control ceases.

Profits, losses, and all other comprehensive income items are attributed to the shareholders' equity of the parent company, and to non-controlling interest, even if this leads to a deficit balance. If need arises, the subsidiaries' financial statements are adjusted accordingly to comply with the Group's accounting policies. All intra-group balances, transactions, unrealized gains and losses resulting from intra-group transactions and dividends are eliminated in full.

**THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY**  
**NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**31 MARCH 2024 (UNAUDITED)**

A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction. If the Group loses control over a subsidiary, it:

- Derecognises the assets (including goodwill) and liabilities of the subsidiary
- Derecognises the carrying amount of any non-controlling interest
- Derecognises the cumulative translation differences recorded in equity
- Recognises the fair value of the consideration received
- Recognises the fair value of any investment retained
- Recognises any surplus or deficit in the statement of profit or loss and other comprehensive income
- Reclassifies the parent's share of components previously recognized in OCI to profit or loss or retained earnings, as appropriate, as would be required if the Group had directly disposed of the related assets or liabilities.

**(3) PROPERTY, PLANT AND EQUIPMENT**

During the three months period ended 31 March 2024, the Company purchased property, plant and equipment by the amount of JD 119,135 (31 March 2023: JD 683,423).

**(4) RELATED PARTIES BALANCES AND TRANSACTIONS**

Related parties represent major shareholders, directors and key management personnel of the Company, associates Company's and entities significantly controlled by them. Pricing policies and terms of the transactions are approved by the Company's management.

Balances with related parties as shown in the interim consolidated statement of financial position are as follows:

	Nature of relationship	31 March 2024 JD (Unaudited)	31 December 2023 JD (Audited)
<b>Due from related parties:</b>			
Jordan Algerian Pharmaceutical Manufacturing Co.	Associate Company	1,182,968	1,182,968
<b>Due to related parties:</b>			
Jordan Algerian Pharmaceutical Manufacturing Co.	Associate Company	983,736	983,736
Azal pharmaceutical company	Associate Company	2,454	2,454
		986,190	986,190
<b>Lease liabilities:</b>			
Jordan Islamic Bank	Major Shareholder	5,966,387	6,624,907
<b>Murabaha financing:</b>			
Jordan Islamic Bank	Major Shareholder	22,104,284	22,254,436
<b>Other liabilities:</b>			
Amounts due to Board of Directors members	Board Members	203,037	197,433

**THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY**  
**NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**31 MARCH 2024 (UNAUDITED)**

The following is a summary of transactions with related parties that appear in the interim consolidated statement of profit or loss:

<u>Nature of relationship</u>		For the three months ended 31 March	
		2024	2023
		JD (unaudited)	JD (unaudited)
<b>Finance costs:</b>			
Jordan Islamic Bank	Major Shareholder	<u>176,819</u>	<u>310,786</u>
<b>Administrative expenses</b>			
Board members transportation allowance	Board Members	<u>18,150</u>	<u>25,300</u>

Short term salaries, transportation and other benefits of key management personnel amounted to JD 43,143 for the period ended 31 March 2024 (for the period ended 31 March 2023: JD 95,325).

**(5) CASH AND CASH EQUIVALENTS**

	31 March 2024	31 December 2023
	JD (Unaudited)	JD (Audited)
Portfolio deposits	7,500	7,500
Bank balances	167,565	593,544
Cash on hand	<u>5,267</u>	<u>14,725</u>
<b>Cash and bank balances</b>	<u>180,332</u>	<u>615,769</u>

**(6) LEASE LIABILITY**

This item includes accrued and unpaid lease installments by the amount of JD 73,263 as at 31 March 2024.

**THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY**  
**NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**31 MARCH 2024 (UNAUDITED)**

---

**(7) INCOME TAX**

**The Jordanian Pharmaceutical Manufacturing Company**

The Company obtained a final clearance from the Income Tax Department until the end of 2020. The Company has also submitted 2021, 2022 and 2023 income tax return to the Income and Sales Tax Department within the legal timeframe.

**Dellas for Natural Products Company-**

The Company obtained a final clearance from the Income Tax Department until the end of 2020. The Company has also submitted 2021, 2022 and 2023 income tax returns to the Income and Sales Tax Department within the legal timeframe.

**Aragen for Technical Organic Company and its subsidiary-**

The Company obtained a final clearance from the Income Tax Department until the end of 2018. The Company has also submitted 2019, 2020, 2021, 2022 and 2023 income tax returns to the Income and Sales Tax Department within the legal timeframe.

**Swagh for Pharmaceutical Manufacturing Company-**

The Company obtained a final clearance from the Income Tax Department until the end of 2018. The Company has also submitted 2019, 2020, 2021, 2022 and 2023 income tax returns to the Income and Sales Tax Department within the legal timeframe.

**Mukalfa Import Export Company-**

The Company submitted 2023 income tax returns to the Income and Sales Tax Department within the legal timeframe.

**(8) LOSS PER SHARE FOR THE PERIOD**

	For the three months period ended 31 March	
	2024	2023
Loss for the period (JD)	(541,837)	(2,166,470)
Weighted average number of shares (share)	69,756,944	69,756,944
	JD/Fils	JD/Fils
Basic and diluted loss per share for the period	(0/008)	(0/031)

**THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY**  
**NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**31 MARCH 2024 (UNAUDITED)**

**(9) SEGMENT INFORMATION**

For management purposes, the Company is organized based on the reports which are used by the General Manager and the main Decision Maker of the Company through the geographical distribution of sales and the geographical distribution of assets and liabilities.

The geographical distribution of sales, cost of sales, gross profit and type of sold items are as follows:

for the three months ended 31 March						
	Inside Jordan		Outside Jordan		Total	
	2024	2023	2024	2023	2024	2023
	JD	JD	JD	JD	JD	JD
Net sales	995,492	1,140,734	1,252,328	903,930	2,247,820	2,044,664
Cost of sales	(672,590)	(1,256,095)	(846,117)	(995,343)	(1,518,707)	(2,251,437)
<b>Gross profit</b>	<b>322,902</b>	<b>(115,361)</b>	<b>406,211</b>	<b>(91,413)</b>	<b>729,113</b>	<b>(206,773)</b>
<b>Other information:</b>						
Depreciation and amortization	221,697	209,295	-	-	221,697	209,295
Finance costs	176,819	310,786	-	-	176,819	310,786

The geographical distribution of assets, liabilities is as follows:

	Inside Jordan		Outside Jordan		Total	
	31 March 2024	31 December 2023	31 March 2024	31 December 2023	31 March 2024	31 December 2023
	JD	JD	JD	JD	JD	JD
Total assets	28,860,230	29,797,031	12,789,263	12,690,442	41,649,493	42,487,473
Total liabilities	41,060,438	41,296,785	1,700,889	1,760,182	42,761,327	43,056,967

**(10) LAWSUITS HELD AGAINST THE COMPANY**

There are cases filed against the company for an amount of JD 698,095 as on 31 March 2024, and this is within the normal activity of the company, and in the discretion of the management and its legal advisor, the company will not have substantial obligations in response to these cases.

**THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY**  
**NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**31 MARCH 2024 (UNAUDITED)**

**(11) COMMITMENTS AND CONTINGENCIES**

As of the date of these interim condensed consolidated financial statements, the Company has the following commitments and contingencies:

	31 March 2024 JD (Unaudited)	31 December 2023 JD (Audited)
<b>Commitments and contingencies:</b>		
Letters of credit	-	-
Bank guarantees	2,646,737	2,649,137
Bills of collection	345,607	146,409

**Associate companies contingent liability:**

The financial statements of The Jordanian Algerian Pharmaceutical Manufacturing Company (49% owned associate company) contain overdraft account issued from The Housing Bank Algeria by the amount of DZD 184.8 million as of 31 December 2024 against 100% guarantee issued from The Jordanian Pharmaceutical Manufacturing Company.

**(12) FAIR VALUES**

The table below analyses financial instruments carried at fair value, by valuation method. The different levels have been defined as follows:

**Level 1:** quoted prices (unadjusted) in active markets for financial assets.

**Level 2:** inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices). This category includes instrument evaluated based on: Prices quoted in active markets for similar instruments or through the use of valuation model that includes inputs that can be traced to markets, these inputs could be defended directly or indirectly.

**Level 3:** inputs for the asset or liability that are not based on observable market data.

**A- Financial assets and liabilities that are measured at fair value:**

	Book value JD	Level 1 JD	Level 2 JD	Level 3 JD
<b>As at 31 March 2024 (Unaudited)</b>				
Financial assets at fair value through other comprehensive income	319,419	-	-	319,419
<b>As at 31 December 2023 (Audited)</b>				
Financial assets at fair value through other comprehensive income	319,419	-	-	319,419

The management believes that the book value of financial assets and liabilities are not materially different from its fair value.

**THE JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY - PUBLIC SHAREHOLDING COMPANY**  
**NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**31 MARCH 2024 (UNAUDITED)**

---

**B- Financial assets and liabilities that are not measured at fair value:**

	<u>31 March 2024</u>	<u>31 December 2023</u>
	JD	JD
<b>Book value</b>	(Unaudited)	(Audited)
Cash and bank balances	180,332	615,769
Due from related parties	1,182,968	1,182,968
Accounts receivables	11,468,515	13,616,143
Checks under collection	647,314	664,855
Lease liabilities	5,966,387	6,624,907
Murabaha financing	22,104,284	22,254,436
Notes payables	4,847,189	5,089,268
Due to related parties	986,190	986,190
Accounts payables	2,418,164	2,446,877

The management believes that the book value of financial assets and liabilities are not materially different from its fair value.